QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold
Plus
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample
collection version of the market-leading modern blood test for latent TB detection
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Tecan Group AG (SIX Swiss Exchange: TECN), a global leader in
laboratory automation and liquid handling technology, announced today a collaboration to improve the processing of QIAGEN’s
QuantiFERON-TB Gold Plus (QFT-Plus) diagnostic test through the utilization of Tecan’s Fluent® Laboratory Automation
workstation for the aliquoting of samples for the optional Lithium Heparin single-tube workflow. The Fluent instruments will be
supplied directly to laboratories through Tecan’s Life Sciences Business.
QIAGEN’s fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection based on
world leading interferon gamma release assay (IGRA) technology.
QuantiFERON-TB Gold Plus offers customers the most flexible workflow among latent TB screening tests, including a single-tube
option that enables efficient screening in large-scale programs by collecting blood samples at patient sites and transporting them
to labs for processing up to 53 hours after venipuncture.
The two parties are working together to optimize a solution that standardizes and automates the manual steps in liquid handling
for the aliquoting of samples. Customers will be able to leverage the high-performance Fluent automation system and thereby achieve
the goal of significantly reducing hands-on time, providing greater ease of use and ensure consistency in pre-analytic methods and
thereby reducing processing errors and variability between runs. Front-end automation solutions also offer laboratories efficient
automation of single tube collection for QuantiFERON, and thereby create efficiency in the lab and improve the patient blood
collection experience.
Please find the full press release
here
###
Investor Relations
John Gilardi
+49 2103 29 11711
Dr. Sarah Fakih
+49 2103 29 11457
e-mail: ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49 2103 29 11826
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com
Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
email: investor@tecan.com
www.tecan.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005610/en/